Wilder R - Search Results

1

Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy.

Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, Medeiros LJ, Notti P, Rassidakis GZ, Peethambaram P, Wilder R, Witzig T, Gianni M, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Visco C, et al. Among authors: wilder r. Leuk Lymphoma. 2004 Oct;45(10):2085-92. doi: 10.1080/10428190410001712234. Leuk Lymphoma. 2004. PMID: 15370254

2

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.

Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. Chronowski GM, et al. Cancer. 2002 Dec 15;95(12):2534-8. doi: 10.1002/cncr.10998. Cancer. 2002. PMID: 12467067 Free article. Clinical Trial.

3

Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.

Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Lee HK, et al. Leuk Lymphoma. 2002 Sep;43(9):1769-75. doi: 10.1080/1042819021000006277. Leuk Lymphoma. 2002. PMID: 12685830

4

International prognostic index-based outcomes for diffuse large B-cell lymphomas.

Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. Wilder RB, et al. Cancer. 2002 Jun 15;94(12):3083-8. doi: 10.1002/cncr.10583. Cancer. 2002. PMID: 12115338 Free article.

5

Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.

Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Schlembach PJ, et al. Cancer J. 2002 Sep-Oct;8(5):377-83. doi: 10.1097/00130404-200209000-00008. Cancer J. 2002. PMID: 12416895

6

Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.

Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Chronowski GM, et al. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):36-43. doi: 10.1016/s0360-3016(02)03915-9. Int J Radiat Oncol Biol Phys. 2003. PMID: 12504034

7

Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.

Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Chronowski GM, et al. Am J Clin Oncol. 2004 Feb;27(1):73-80. doi: 10.1097/01.coc.0000045853.73233.42. Am J Clin Oncol. 2004. PMID: 14758137

8

Localized non-Hodgkin lymphoma involving the thyroid gland.

Ha CS, Shadle KM, Medeiros LJ, Wilder RB, Hess MA, Cabanillas F, Cox JD. Ha CS, et al. Among authors: wilder rb. Cancer. 2001 Feb 15;91(4):629-35. Cancer. 2001. PMID: 11241227

9

Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.

Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Wilder RB, et al. Cancer. 2001 Jun 15;91(12):2440-6. Cancer. 2001. PMID: 11413536

10

Long-term results with radiotherapy for Stage I-II follicular lymphomas.

Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P, Hess MA, Cabanillas F, Cox JD. Wilder RB, et al. Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27. doi: 10.1016/s0360-3016(01)01747-3. Int J Radiat Oncol Biol Phys. 2001. PMID: 11728680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

635 results

Search Page

Filters